NextCure, Inc. Files 8-K Report

Ticker: NXTC · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1661059

Nextcure, Inc. 8-K Filing Summary
FieldDetail
CompanyNextcure, Inc. (NXTC)
Form Type8-K
Filed DateDec 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-k

Related Tickers: NXTC

TL;DR

NextCure filed a routine 8-K on Dec 5th. Nothing major disclosed yet.

AI Summary

On December 5, 2024, NextCure, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates NextCure, Inc. is complying with regulatory reporting requirements, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory compliance and does not disclose any new material risks or events.

Key Players & Entities

  • NextCure, Inc. (company) — Registrant
  • December 5, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing for NextCure, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing's item information.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is NextCure, Inc.

In which state was NextCure, Inc. incorporated?

NextCure, Inc. was incorporated in Delaware.

What is the principal executive office address for NextCure, Inc.?

The address of the principal executive offices is 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.

What is the telephone number for NextCure, Inc.?

The registrant's telephone number, including area code, is (240) 399-4900.

Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-05 07:11:10

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On December 5, 2024, NextCure, Inc. (the "Company") updated its corporate presentation to reflect that it has filed an Investigational New Drug Application for its product candidate LNCB74. Beginning on December 5, 2024, the Company will be engaging with members of the investment community, which may reference these presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.1. The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing . .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 NextCure, Inc. Presentation dated December 5, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: December 5, 2024 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.